Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2015 | Research article

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa

Authors: R. Somayaji, B. Waddell, M. L. Workentine, M. G. Surette, N. P. Brager, H. R. Rabin, M. D. Parkins

Published in: BMC Pulmonary Medicine | Issue 1/2015

Abstract

Background

Epidemic P. aeruginosa (ePA) infections are common in cystic fibrosis (CF) and have been associated with accelerated clinical decline. Factors associated with ePA are unclear, and evidence based infection control interventions are lacking.

Methods

We prospectively collect all bacterial pathogens from adult CF patients. We performed PA strain typing on retrospectively collected enrolment samples and recent isolates to identify patients infected with ePA. All patients attending our clinic were approached to complete a survey on infection control knowledge, beliefs and exposures. We analyzed responses of those with ePA relative to the entire cohort without ePA as well as those infected with unique strains of P. aeruginosa to assess for risk factors for ePA and differences in infection control knowledge, beliefs or behaviours.

Results

Of 144 participants, 30 patients had ePA (two Liverpool epidemic strain, 28 Prairie epidemic strain), 83 % of which had established infection prior to transition to the adult clinic. Risk of concomitant infecting pathogens was no different between groups although, Staphylococcus aureus and non-tuberculous mycobacteria were less common in those with ePA. Patients with ePA were more likely to have attended CF-camp and have a history of CF fundraising. Patients with ePA did not differ with respect to beliefs regarding pathogens or transmission risk, except they believed indirect contact posed little risk. Furthermore, patients with ePA were more likely to continue to associate with others with CF despite extensive counselling. Use of peer-peer online networking was minimal in both groups.

Conclusion

Infections with ePA are closely linked to past exposures, now routinely discouraged. As socialization is the greatest risk factor for ePA, infection control strategies for ePA must focus on discouraging face-to-face interactions amongst CF patients. As peer support remains a desire amongst patients, investment in technologies and strategies that enable indirect communication and support are required.

Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639–42.CrossRefPubMed

Aaron SD, Vandemheen KL, Ramotar K, Giesbrecht-Lewis T, Tullis E, Freitag A, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA. 2010;304(19):2145–53.CrossRefPubMed

Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol. 2004;53(Pt 7):609–15.CrossRefPubMed

Martin K, Baddal B, Mustafa N, Perry C, Underwood A, Constantidou C, et al. Clusters of genetically similar isolates of Pseudomonas aeruginosa from multiple hospitals in the UK. J Med Microbiol. 2013;62(Pt 7):988–1000.CrossRefPubMed

Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ. Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)--a cause for concern? J Cyst Fibros. 2012;11(3):173–9.CrossRefPubMed

Armstrong DS, Nixon GM, Carzino R, Bigham A, Carlin JB, Robins-Browne RM, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med. 2002;166(7):983–7.CrossRefPubMed

Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol. 2014;52(4):1127–35.PubMedCentralCrossRefPubMed

O’Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Coulter C, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J. 2004;24(1):101–6.CrossRefPubMed

Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J. 2012;40(1):227–38.CrossRefPubMed

10.

Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax. 2004;59(4):334–6.PubMedCentralCrossRefPubMed

11.

Jones AM, Dodd ME, Morris J, Doherty C, Govan JR, Webb AK. Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest. 2010;137(6):1405–9.CrossRefPubMed

12.

Poonja A, Workentine, M, Waddell, B, Surette, MG, Duong, J, DG Storey, Gregson, D, Rabin, HR and MD Parkins. Development and validation of a PCR assay to detect the Prairie Epidemic Strain (PES) of Pseudomonas aeruginosa. In. Ped Pulmonol: 2015; Phoenix, AZ; 2015.

13.

Somayaji RLJ, Surette M, Waddell B, Purighalla S, Sibley C, Rabin H, et al. Clinical outcomes of chronic ‘Prairie Epidemic Strain’ Pseudomonas aeruginosa infection in adults with cystic fibrosis. In: 38th Annual European Cystic Fibrosis Conference. Brussels: Journal of Cystic Fibrosis; 2015. 2015.

14.

Masterson TL, Wildman BG, Newberry BH, Omlor GJ. Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. Pediatr Pulmonol. 2011;46(3):295–301.CrossRefPubMed

15.

Sibley CD, Sibley KA, Leong TA, Grinwis ME, Parkins MD, Rabin HR, et al. The Streptococcus milleri population of a cystic fibrosis clinic reveals patient specificity and intraspecies diversity. J Clin Microbiol. 2010;48(7):2592–4.PubMedCentralCrossRefPubMed

16.

Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29–34.CrossRefPubMed

17.

Walter S, Gudowius P, Bosshammer J, Romling U, Weissbrodt H, Schurmann W, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax. 1997;52(4):318–21.PubMedCentralCrossRefPubMed

18.

Varekojis SM, Douce FH, Flucke RL, Filbrun DA, Tice JS, McCoy KS, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. Respir Care. 2003;48(1):24–8.PubMed

19.

Saint S, Greene MT, Olmsted RN, Chopra V, Meddings J, Safdar N, et al. Perceived strength of evidence supporting practices to prevent health care-associated infection: results from a national survey of infection prevention personnel. Am J Infect Control. 2013;41(2):100–6.PubMedCentralCrossRefPubMed

20.

Tummler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29(6):1265–7.PubMedCentralPubMed

21.

Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol. 2000;29(3):177–81.CrossRefPubMed

22.

Walsh NM, Casano AA, Manangan LP, Sinkowitz-Cochran RL, Jarvis WR. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. J Pediatr. 2002;141(4):512–7.CrossRefPubMed

23.

Razvi S, Quittell L, DiMango E, Andersen J, Sewell W, Garber E, et al. Abstract 348: CF patients and families’ perspectives of infection control recommendations. Pediatr Pulmonol. 2006;S29(S29):329–30.

24.

Miroballi Y, Garber E, Jia H, Zhou JJ, Alba L, Quittell LM, et al. Infection control knowledge, attitudes, and practices among cystic fibrosis patients and their families. Pediatr Pulmonol. 2012;47(2):144–52.CrossRefPubMed

25.

Clifton IJ, Peckham DG. Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis. Expert Rev Respir Med. 2010;4(4):519–29.CrossRefPubMed

26.

Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect. 1983;4(1):31–40.CrossRefPubMed

27.

Wainwright CE, France MW, O’Rourke P, Anuj S, Kidd TJ, Nissen MD, et al. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax. 2009;64(11):926–31.PubMedCentralCrossRefPubMed

28.

Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1–S67.CrossRefPubMed

29.

Zuckerman JB, Clock SA, Prato BS, McDevitt JJ, Zhou JJ, Leclair LW, et al. Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies. Am J Respir Crit Care Med. 2015;191(5):598–601.CrossRefPubMed

30.

Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ. Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Rep. 2013;4(1):1.PubMedCentralCrossRefPubMed

31.

Griffiths AL, Jamsen K, Carlin JB, Grimwood K, Carzino R, Robinson PJ, et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med. 2005;171(9):1020–5.CrossRefPubMed

32.

Matt B, Mitteregger D, Renner S, Presterl E, Assadian O, Diab-Elschahawi M. Successful implementation of infection control strategies prevents P. aeruginosa transmission among cystic fibrosis patients inside the hospital. GMS hygiene and infection control. 2014;9(3):Doc20.PubMedCentralPubMed

33.

Saiman L, Garber E. Infection control in cystic fibrosis: barriers to implementation and ideas for improvement. Curr Opin Pulm Med. 2009;15(6):626–31.CrossRefPubMed

34.

Jones AM, Dodd ME, Govan JR, Doherty CJ, Smith CM, Isalska BJ, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med. 2005;171(3):257–60.CrossRefPubMed

35.

McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet. 2001;358(9281):558–60.CrossRefPubMed

36.

Garber E, Desai M, Zhou J, Alba L, Angst D, Cabana M, et al. Barriers to adherence to cystic fibrosis infection control guidelines. Pediatr Pulmonol. 2008;43(9):900–7.CrossRefPubMed

37.

MY CF CANADA NETWORK [http://www.mycfnetwork.com]

38.

Kirk S, Milnes L. An exploration of how young people and parents use online support in the context of living with cystic fibrosis. Health Expectations. 2015. doi:10.1111/hex.12352. [Epub ahead of print].

Title: Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa
Authors: R. Somayaji
B. Waddell
M. L. Workentine
M. G. Surette
N. P. Brager
H. R. Rabin
M. D. Parkins
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Pulmonary Medicine / Issue 1/2015
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-015-0116-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease

Patients’ perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy

Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease

A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosa

Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE)

Effects of controlled diesel exhaust exposure on apoptosis and proliferation markers in bronchial epithelium – an in vivo bronchoscopy study on asthmatics, rhinitics and healthy subjects

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page